This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47. doi: 10.1111/j.1365-2516.2012.02909.x.SrivastavaABrewerAKMauser-BunschotenEPGuidelines for the management of hemophiliaHaemophilia201319e14710.1111/j.1365-2516.2012.02909.x22776238Open DOISearch in Google Scholar
Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5): 660–7. doi: 10.1111/hae.12169.HayCRPurchasing factor concentrates in the 21st century through competitive tenderingHaemophilia2013195660710.1111/hae.1216923711201Open DOISearch in Google Scholar
NovoEight® Summary of Product Characteristics, April 2018. Available from https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf (accessed 27 April 2020).NovoEight® Summary of Product CharacteristicsApril2018Available from https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf (accessed 27 April 2020)Search in Google Scholar
Pollard D, Khair K, Holland M. Switching factor products: nurses’ experience with NovoEight. J Haem Pract 2020; 7(1): 59–69. doi: 10.17225/jhp00156.PollardDKhairKHollandMSwitching factor products: nurses’ experience with NovoEightJ Haem Pract202071596910.17225/jhp00156Open DOISearch in Google Scholar
Chaugule SS, Hay JW, Young G. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence 2015; 9:1623–30. doi: 10.2147/PPA.S92985.ChauguleSSHayJWYoungGUnderstanding patient preferences and willingness to pay for hemophilia therapiesPatient Prefer Adherence2015916233010.2147/PPA.S92985464660026635471Open DOISearch in Google Scholar
Remor E. Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients. Haemophilia 2011; 17(5): e901–5. doi: 10.1111/j.1365-2516.2011.02578.x.RemorEPredictors of treatment difficulties and satisfaction with haemophilia therapy in adult patientsHaemophilia2011175e901510.1111/j.1365-2516.2011.02578.x21649798Open DOISearch in Google Scholar
Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713–20. doi: 10.2147/PPA.S64709.CiminoELinariSMalerbaMHalimehSBiondoFWestfeldMPatient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countriesPatient Prefer Adherence2014817132010.2147/PPA.S64709427029925525348Open DOISearch in Google Scholar
Pollard D, Khair K, Percier C, Wong Y, Shoemark R. Evaluation of MixPro® among users and nurses. J Haem Pract 2017; 5(1): 12–23. doi: 10.17225/jhp00106.PollardDKhairKPercierCWongYShoemarkREvaluation of MixPro® among users and nursesJ Haem Pract201751122310.17225/jhp00106Open DOISearch in Google Scholar
Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19(5): 698–705. doi: 10.1111/hae.12165.KulkarniRKarimFAGlamocaninSResults from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokineticsHaemophilia201319569870510.1111/hae.1216523651313Open DOISearch in Google Scholar
Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19(5): 691–7. doi: 10.1111/hae.12159.LentzSRMisgavMOzeloMResults from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacyHaemophilia2013195691710.1111/hae.1215923647704Open DOISearch in Google Scholar
Lentz SR, Janic D, Kavakli K, et al. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Haemophilia 2018; 24(6): e391–e394. doi: 10.1111/hae.13617.LentzSRJanicDKavakliKLong-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trialHaemophilia2018246e391e39410.1111/hae.1361730402994Open DOISearch in Google Scholar
Brand-Staufer B, Dahl PW, Johansen SD, Nohr AM. Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling. Presented at WFH 2018 World Congress, Glasgow, UK, 21 May 2018.Brand-StauferBDahlPWJohansenSDNohrAMTuroctocog alfa is stable during storage at 40°C and multiple sequences of temperature cyclingPresented at WFH 2018 World CongressGlasgow, UK21 May 2018Search in Google Scholar
Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence 2018; 12: 431–41. doi: 10.2147/PPA.S151812.TischerBMarinoRNapolitanoMPatient preferences in the treatment of hemophilia A: impact of storage conditions on product choicePatient Prefer Adherence2018124314110.2147/PPA.S151812587558829618923Open DOISearch in Google Scholar
Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med 2017; 8: 67–73. doi: 10.2147/JBM.S103796.LieuwKMany factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?J Blood Med20178677310.2147/JBM.S103796547926228670147Open DOISearch in Google Scholar
, 